ClinicalTrials.gg

Osteosarcoma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 488 studies for Osteosarcoma across more than 10 countries. 123 are recruiting or about to start. 218 of them are mainly about Osteosarcoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Sarcoma, Ewing too: 622 studies, 154 open.

Status

Completed
214
Recruiting
100
Status unknown
44
Terminated
41
Active, not recruiting
41
Not yet recruiting
20

Phase

Phase 2
216
Phase 1
153
Phase 3
21
Early Phase 1
9
Phase 4
2

Where

United States
278
China
60
Canada
37
France
36
Italy
33
Puerto Rico
25

Who develops what

Add Osteosarcoma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 4 programs from 4 companies, 4 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Hansoh Pharmaceutical Group and Lantheus here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
GemcitabineRecent, limited
Evidence
  • NCT06935409 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · comparator · “Gemcitabine combined with docetaxel” · registered Apr 2025
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed11 study
DocetaxelRecent, limited
Evidence
  • NCT06935409 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · comparator · “Gemcitabine combined with docetaxel” · registered Apr 2025
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Aug 2027 est.Lutetium Lu 177-DOTA-DUNP19 LNTH2403 · Lantheus Holdings, Inc. · Phase 2 main aimNCT07357519 Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) — primary endpoint: To identify the maximum tolerated dose (MTD) of LNTH-2403 in participants with R/R osteosarcoma (Ph1) · 55 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Osteosarcoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 14 open · Antimetabolites 5 open · Immune checkpoint inhibitors 5 open · Alkylating agents 4 open · Angiogenesis inhibitors 3 open

Coming up

46studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger. 75 (75%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 3 (3%) take healthy volunteers.

Recruiting studies that take each age, of 100
AgeWomenMen
1052 (52%)52 (52%)
1897 (97%)96 (96%)
3086 (86%)85 (85%)
4075 (75%)74 (74%)
5065 (65%)65 (65%)
6559 (59%)59 (59%)
7552 (52%)52 (52%)
8543 (43%)43 (43%)

Across all 488 studies, recruiting or not: 57% stop at 75 or younger and 51% at 65; 81% take children; <1% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Osteosarcoma studies take

Of 76 phase 2 interventional studies under Osteosarcoma, half reached primary completion within 65 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 177 mo54–134 · 49 studies——
Phase 1/277 mo40–92 · 33 studies——
Phase 265 mo40–94 · 76 studies—66 mo41–94 · 72 studies
Interventional, no phase53 mo14–114 · 22 studies——
Observational76 mo40–228 · 41 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 488. Browse all 488 → or search them.